The new fund will assist individuals with out-of-pocket medical expenses associated with their condition and treatment, including copayments and coinsurance, health insurance premiums and incidental medical expenses.
People with atypical hemolytic-uremic syndrome experience kidney damage and acute kidney failure that lead to end-stage renal disease in about half of all cases.
The condition can occur at any age and is estimated to affect 1 in 500,000 people per year in the United States.
The Assistance Fund helps patients and families facing high medical out-of-pocket costs by providing financial assistance for their copayments, coinsurance, deductibles, and other health-related expenses.
It currently manages more than 30 funds, each of which covers the FDA-approved medications that treat a specific disease. Since its founding in 2009, The Assistance Fund has helped more than 43,000 adults and children access the medicines they need to stay healthy or manage a chronic condition.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval